Lucira Health, Inc. (LHDX)
| Market Cap | 459.75M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -22.20M |
| Shares Out | 37.05M |
| EPS (ttm) | -0.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $12.00 |
| Previous Close | $13.88 |
| Change ($) | -1.88 |
| Change (%) | -13.54% |
| Day's Open | 13.54 |
| Day's Range | 11.61 - 14.40 |
| Day's Volume | 794,074 |
| 52-Week Range | 11.61 - 37.99 |
EMERYVILLE, Calif.--(BUSINESS WIRE)--Lucira Health, Inc. (Nasdaq: LHDX), today announced that U.S. physicians and healthcare providers can now order Lucira COVID-19 All-In-One Test Kits online...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and inno...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and inno...
Lucira Health, which is developing single-use test kits for COVID-19 and other infectious diseases, filed on Friday with the SEC to raise up to $115 million in an initial public offering.
Lucira Health, Inc. has filed to go public with an IPO on the NASDAQ.
Amid surging coronavirus cases, the top U.S. testing official on Thursday announced another scale-up in the country’s diagnostic efforts, touting the importance of tests that can run from star...
About LHDX
Lucira Health, a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops testing platform that provides molecular testing services. The company offers LUCIRA COVID- 19 All- In- One Test Kit, that provides COVID- 19 result; and develops influenza A and B viruses test kits. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was founded in 2013 and is headquartered in Emeryville, California.
| Industry Diagnostics & Research | IPO Date Feb 5, 2021 |
| CEO Erik T. Engelson | Employees 57 |
| Stock Exchange NASDAQ | Ticker Symbol LHDX |